OrbusNeich Begins Dual Therapy Stent Study
OrbusNeich has enrolled the first U.S. percutaneous coronary intervention patients in its new stent study, the Hong Kong-based devicemaker announced Monday.
The clinical trial will evaluate the company’s Combo dual therapy stent which was developed to repair vessel injury and regenerate endothelium, which lines the vessels. It is the only stent in the world capable of doing this, the company claims.
The clinical trial is being carried out under the auspices of the Japan-U.S. Harmonization-By-Doing initiative, and is intended to support the devicemaker’s application for Japanese Shonin approval and meet U.S. feasibility trial requirements.
A total of 572 patients will be enrolled at up 50 locations in Japan and the U.S. — Jason Scott